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Objective: To investigate total bile acid (TBA) levels in maternal (MB) and umbilical cord blood (UCB) in normo-
tensive, preeclamptic (PE), and PE pregnancies complicated by hemolysis elevated liver enzymes and low plate-
lets (HELLP) syndrome in the context of ABCG2 placental gene expression levels, a recently reported placental
bile acid transporter.
Methods: TBA levelswere determined in 83 pairedMB and UCB samples of normotensive, PE and PE/HELLP preg-
nancies and in 22 paired arterial and venous UCB samples fromuncomplicated termpregnancies.ABCG2 gene ex-
pressionwasmeasured in 104 human placentas by reverse transcriptase quantitative polymerase chain reaction.
Results: Overall, TBA levels in MB are higher compared to levels in UCB (p b 0.0001), but this comparison looses
statistical signiﬁcance for the 11 PE/HELLP cases. TBA levels in maternal blood are increased in PE/HELLP com-
pared to PE pregnancies (p= 0.016). TBA levels in arterial and venous UCB from 22 normotensive pregnancies
are not statistically different. ABCG2 expression is reduced in pregnancies where preeclampsia is further compli-
cated by HELLP syndrome. ABCG2 expression in human placenta is not correlated with TBA levels in either the
maternal or fetal compartment.
Conclusion: Increased maternal TBA levels in PE/HELLP pregnancies indicate a relation between bile acids in the
maternal circulation and HELLP syndrome. As overall TBA levels in maternal blood are increased compared to
UCB, we conclude that the placenta partly protects the fetus from increased maternal TBA levels. This consistent
difference in TBA levels between the maternal and fetal compartment is unrelated to the placental expression of
ABCG2.© 2014 Elsevier B.V. All rights reserved.1. Introduction
The placenta serves different functions crucial for fetal growth and
development. Apart from producing nutrients, energy, growth factors,
cytokines, and hormones, the placenta is essential for the exchange of
oxygen, nutrients andwaste between thematernal and fetal circulation
[1,2].amural research funds of the
linic, Academic Medical Center,
1100 DD, The Netherlands.Preeclampsia (PE) is characterized by new onset hypertension after
20 weeks of gestation combinedwith proteinuria and is a major risk for
both mother and fetus [3]. Although clinical symptoms manifest in the
secondhalf of pregnancy, thepathophysiologicalmechanism is aberrant
placentation, and this occurs in the ﬁrst and early second trimester of
pregnancy [4]. Subsequent aberrant release of placental produced fac-
tors such as sFLT1 into the maternal circulation cause endothelial dys-
function [5].
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-speciﬁc
disorder that usually presents in the third trimester. ICP is diagnosed
by increased non-fasting or fasting serum total bile acid (TBA) levels
and maternal pruritus [6]. PE complicates 8–25% of pregnancies that
are affected by ICP [7–9], which is higher than the PE incidence in the
general population (1.5–6%) [10–12], suggesting a putative relation be-
tween bile acids and the pathogenesis of PE. About 10–20% of severe
Table 1
Clinical characteristics summary of studied groups. Data are represented as median
(range) or numbers (%). p-values were calculated by Mann–Whitney U test*, chi-square#
or Fisher's exact test§. Abbreviations: n.a. not applicable; n.d. not determined; n.s. not
signiﬁcant.
Clinical parameter Normotensive,
n = 59
Preeclamptic,
n = 45
p-value
Maternal age (years) 28 (18–38) 31 (18–41) p b 0.05*
BMI (kg/m2) 22.2 (17.3–42.5) 25.3 (17.5–36.2) n.s.*
Nulliparous 30 (51%) 26 (58%) n.s.#
Highest diastolic BP (mmHg) 71 (60–94) 100 (90–120) p b 0.001*
Urinary protein (g/24 h) n.d. 2.1 (0.3–32.4) n.a.
HELLP 0 (0%) 17 (38%) p b 0.001§
Primary caesarean section 5 (8%) 21 (46%) p b 0.001#
Gestational age at delivery
(weeks)
34+1 (26+3–
42+0)
34+4 (28+1–
41+0)
n.s.*
Delivery 34-37 weeks
gestation
9 (15%) 5 (11%) n.s.#
Delivery b34 weeks gestation 23 (39%) 21 (47%) n.s.#
Neonatal weight (g) 2375 (860–
5300)
1810 (780–
3990)
p b 0.05*
Birth percentile b10 3 (5%) 7 (16%) n.s.§
Maternal and umbilical cord
blood available
52 (88%) 31 (69%) n.a.
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ed liver enzymes and low platelets (HELLP) syndrome [13].We recently
reported a series of fourwomenwith seven pregnancies where ICP pre-
ceded the occurrence of severe HELLP syndrome in 5 pregnancies [14],
suggesting that increased TBA levels relate to the development of
HELLP syndrome. Further illustration of the pathophysiological relation
between PE and ICP is the fact that increased numbers of syncytial knots
have been described in placentas from pregnancies complicated by ICP
[15], a hallmark of PE [16].
Cholestatic effects of reproductive hormones and their metabolites
in genetically susceptible women are considered causal to the increased
maternal TBA levels [17,18].
Bile acids are present in the fetal compartment as early as 13 weeks
of human gestation [19]. Over 90% of fetal bile acids are conjugated
forms of the primary bile acids cholic acid and chenodeoxycholic acid
[20]. Intestinal bacteria necessary to transform primary bile acids into
secondary bile acids are thought to be absent in utero. The
enterohepatic circulation of bile acids in utero as opposed to adult life
is minimal [21]. In theory, the fetus is able to contribute to thematernal
TBA pool as about 80% of the maternal TBA in pregnancies complicated
by ICP consists of the primary bile acid cholic acid [20].
The umbilical cord functions as a “pipeline” between the placental
and fetal compartment and contains 1 vein and 2 arteries. The umbilical
vein carries oxygen- and nutrient-rich blood from placenta to fetus. The
arteries transport deoxygenated blood andwaste products from fetus to
placenta.
Although transfer from thematernal to the fetal circulation has been
documented [22], it is generally believed that fetal primary bile acids are
transferred across the placenta into thematernal circulationwhere they
are eliminated by the maternal liver [23]. This implies increased levels
in the umbilical artery compared to the umbilical cord vein as has
been demonstrated using gas chromatography [24]. Several bile acid
transporter proteins or proteins associated with cholestatic disease are
expressed in human placenta [25]. ABCG2 and ABCB11, members of
the ABC-transporter family, are able to transfer bile acids [26]. Although
ABCB11 is the main bile acid transporter in liver, its expression in
human placenta is negligible [25]. Human ABCG2 overexpressed in Chi-
nese hamster ovary cells results in bile transport across the plasma
membrane [27]. Fetuses from homozygous Abcg2 knockout mice show
amarkedly higher increase in levels of bile acids in their serum after ob-
structive cholestasis than their wild-type counterparts [27]. In wild-
type mice, obstructive cholestasis does not lead to a difference in pla-
cental Abcg2mRNA expression, while in maternal serum, this increase
is similar in knockout and wild-type mice. In rodents, Abcg2 appears
to be a prominent placental bile transporter [27]. ABC transporters in
placenta are known to protect the fetus from xenobiotics and cellular
accumulation of cytotoxic compounds [28].
In this study, we investigate TBA levels in the maternal and fetal
compartment in normotensive, PE and PE/HELLP pregnancies and relate
these levels to the expression of ABCG2 in placenta. Because of conﬂict-
ing reports [20,29,24,30] to ﬁrmly establish if net bile acid transport
across the placenta does or does not occur, we additionally analyzed
TBA levels in paired arterial and venous UCB samples in normotensive
term controls.
2. Methods
2.1. Biosamples and patient data
Biosamples were collected through the PE And Non-PE DAtabase
(PANDA); an obstetrical biosample effort, approved by the institutional
review board of the Academic Medical Center, where we obtained
placenta biopsies, venous UCB, and maternal blood (not necessarily
fasting samples) at the time of deliverywith informed consent. Placenta
biopsies (59 normotensive controls and 28 PE and 17 patients with PE
complicated by HELLP syndrome) were taken from macroscopicallyviable (non-infarcted) cotyledons at the maternal side within 2 h of
delivery, placed in RNAlater (Ambion), processed according to the
manufacturer's instructions and stored at −80 °C until use. Clinical
data are listed in Supplementary Table 1. From 83 of the in total 104
included pregnancies, both UCB heparin plasma samples and maternal
heparin plasma samples stored at −80 °C were available. They were
used for comparison of TBA levels in maternal and UCB and to test if
there is correlation between TBA levels and the expression level of
ABCG2.
Additionally, paired arterial and venous umbilical cord heparin plas-
ma samples were taken immediately after birth from 22 anonymously
collected placentas from normotensive term pregnancies.
PE was deﬁned by two systolic blood pressure measurements
of ≥140 mmHg, or diastolic measurements of ≥90 mmHg, at least 6 h
apart after 20 weeks' gestation in a previously normotensive patient in
combination with new-onset proteinuria (N0.3 g/24-h or at least N1+
on protein dipstick when urine could not be collected for 24 h) [31]. Pa-
tients with baseline hypertension or renal disease were excluded. HELLP
syndrome was deﬁned by lactate dehydrogenase ≥600 U/L or haptoglo-
bin b0.2 g/L, aspartate or alanine aminotransferase≥70 U/L, and platelet
count b100 *109/L [32]. Apparently healthy, normotensive pregnant
women were included as controls.
2.2. Measurement of TBA levels
TBA levels were quantiﬁed using the Diazyme total bile acids kit
(Diazyme Laboratories, Poway, CA), according to the manufacturer's
instructions.
2.3. Tissue preparation and reverse transcriptase quantitative polymerase
chain reaction (RT-qPCR)
RNA was isolated using the MagNA Pure LC RNA Isolation Kit High
Performance (Roche), and reverse transcribed using AMV First Strand
cDNA Synthesis Kit for reverse transcription (RT)-PCR (Roche). RT-
qPCR was performed in duplicate on a LightCycler 480 system (Roche)
according to themanufacturer's protocolwith 0.4 μmol/L of each primer
(Invitrogen), 100 nmol/L UPL probe (Roche), and 5 μl Absolute RT-qPCR
mix (ThermoScientiﬁc). Primerswere designed using the RocheUniver-
sal ProbeLibrary Assay Design Center (Supplementary Table 2).
Data were analyzed and quantiﬁed, using the second derivative
maximum for Cp determination, with the LightCycler 480 software
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Fig. 1. TBA levels in normotensive (NT) pregnancies and pregnancies complicated by pre-
eclampsia (PE). (A) TBA levels in paired maternal blood (MB) and umbilical cord blood
(UCB) samples (n= 83). Data are shown as median (thick line) with interquartile range
(box limits) andminimumandmaximumvalues (whisker limits). (B) TBA levels in paired
arterial and venous UCB samples from normotensive term pregnancies (n= 22). Differ-
ences were tested either byWilcoxonmatched-pairs signed rank test§ or Mann–Whitney
U# test with Bonferroni correction.
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as a reference gene for normalization.
2.4. Western blot analysis and correlation of ABCG2 protein levels to mRNA
levels
The anti-ABCG2 antibody BXP-21 [33] was used for Western blot
analysis of ABCG2 on placental samples from 6 normotensive patients,
6 PE patients, and 6 patients with PE/HELLP. Samples were selected
based on most extreme levels of mRNA expression within their group
as well as sufﬁcient sample availability for protein analysis. β-Actin
was used for semi-quantitative normalization.
Placenta biopsies were homogenized by a 2-min polytron treatment
after adding ice-cold Ripa buffer (50 mMNaCl, 50 mM Tris–HCl pH 8.0,
1% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate), supplemented
with complete EDTA-free protease inhibitor cocktail (Roche) and
Phospostop (Roche). Next, the differential centrifugation of homoge-
nates was 10.000×g for 10 min at 4 °C and the subsequent spinning of
the supernatant was 36,0000×g for 70 min at 4 °C. Protein concentra-
tion in the supernatantwas determined by a BCAProtein-assay (Pierce).
Equal amounts of protein samples were separated by SDS–PAGE (4–
12%) and transferred electrophoretically to Immobilo-FL Hydrophobic
PVDF-membrane (Milipore). For the detection of ABCG2 monoclonal
antibody BXP-21 (1:500) and for β-actin, monoclonal antibody AC-15
(Sigma, 1:15000) was used. Primary antibody binding was visualized
by infrared dye-labeled secondary antibody IRDye 800 Goat anti-
Mouse (Li-Cor), followed by a scan on an Odyssey Imager (Li-Cor).
Quantiﬁcation of the signal was performed by Imaging Studio Lite ver-
sion 4.0 software (Li-Cor).
2.5. Statistical analysis
The p-values b0.05 were considered statistically signiﬁcant. Group
differences were tested using a Mann–Whitney U test with Bonferroni
correction when applicable or a Kruskal–Wallis test to compare multi-
ple groups (Fig. 1A). Correlations were analyzed by Spearman's rank
correlation. Paired Wilcoxon matched-pairs signed rank test was used
to compare values of paired arterial and venous UCB samples and of
paired maternal blood and UCB samples. GraphPad Prism 6 (GraphPad
Software, Inc) was used as statistical package and for graphical
representation.
3. Results
3.1. Biosampling
Patient characteristics of both groups are comparable with the
exception of maternal age (Table 1). Parameters relating to PE (highest
maternal diastolic blood pressure and neonatal weight) are statistically
different between groups. As PE/HELLP is an important contributor to
iatrogenic preterm delivery the primary caesarean section rate is also
increased in this patient group (Supplementary Table 1).
3.2. TBA determinations in maternal blood (MB) and umbilical cord blood
(UCB).
Overall, median TBA levels in MB are higher compared to median
TBA levels in UCB (p b 000.1)
After splitting the total group in subgroups, this comparison looses
statistical signiﬁcance for the 11 PE/HELLP cases. In both normotensive
and PE pregnancies (ranging from 26+2 to 42+0weeks of gestation),
median TBA levels inmaternal blood (6.7 μmol/l and 11.5 μmol/l respec-
tively) are higher compared tomedian TBA levels in UCB (p=0.007 and
p b 0.001, respectively). Compared to normotensive andPEpregnancies,
median TBA levels in maternal blood from PE/HELLP pregnancies (14.9
μmol/l) are increased (p= 0.003 and p= 0.032, respectively). MedianTBA levels in UCB between normotensive, PE and PE/HELPP pregnancies
are statistically different when tested with Kruskal–Wallis test (median
TBA levels 5.6 μmol/L in both normotensive UCB and PE UCB, and 7.7
μmol/L in HELLP UCB) (Fig. 1A). When group differences are compared
with Mann–Whitney U test and corrected with Bonferroni correction,
only the difference in TBA levels between levels in UCB of HELLP pa-
tients compared to levels in UCB in PE patients is statistically different
(p= 0.018) (Fig. 1A).
TBA levels measured in both maternal blood and UCB show no cor-
relation in relation to gestational age either in normotensive controls,
PE patients or HELLP patients (p-values of Spearman's correlation coef-
ﬁcient all not signiﬁcant, data not shown).
TBA levels in arterial and venous UCB from 22 normotensive preg-
nancies are not statistically different with 4.25 μmol/L (0.1–11.4 μmol/
L) versus 4.28 μmol/L (0.1–12.9 μmol/L), respectively (Fig. 1B).3.3. ABCG2 expression in human placenta
To investigate if ABCG2 (ATP-binding cassette sub-family Gmember
2) is involved in TBA distribution between the maternal and the fetal
pool or could play a role in protecting the fetal circulation from the in-
creased maternal TBA levels in case of a PE/HELLP pregnancy, we
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levels in both the maternal and the fetal compartment.
ABCG2 is expressed in human placenta from at least 26 + 2 to 42
weeks of gestation (Fig. 2D). In placenta, ABCG2 is an abundantly
expressed transcript with a median normalized expression of 9.1
(range: 0.6–32.2), especially high in contrast to placental expression
of the hepatic bile acid transporter ABCB11 that in our series is N1000-
fold lower (median normalized expression 0.001, with a range of zero
to 0.48) (data not shown). There is no difference in ABCG2mRNA ex-
pression levels between normotensive controls and PE placenta's
(Fig. 2A). ABCG2mRNA expression levels are reduced in PE pregnancies
complicated byHELLP syndrome either compared to PE pregnancies not
complicated by HELLP syndrome (p= 0.033) (Fig. 2B) or compared to
all (both normotensive and preeclamptic) pregnancies not complicated
by HELLP syndrome (p= 0.017) (Fig. 2C). With a Spearman's correla-
tion coefﬁcient of 0.21 (p=0.04), ABCG2 expression is weakly correlat-
ed to gestational age (Fig. 2D).
3.4. ABCG2 gene expression in relation to maternal or UCB TBA levels
There is no statistical signiﬁcant relationwith eithermaternal or UCB
TBA levels with placental expression of ABCG2 (data not shown).
There is no correlation between the Δ ([TBA] maternal-[TBA] UCB)
and the expression of ABCG2 (p= 0.65) in placenta (data not shown).
3.5.Western blot analysis and comparison of ABCG2 protein levels tomRNA
levels
The anti-ABCG2 antibody BXP-21was used forWestern blot analysis
of ABCG2 on placental samples from 6 normotensive patients, 6 PE pa-
tients, and 6 patients with PE/HELLP. β-Actin was used for semi-N
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Fig. 2. Comparison of RT-qPCR expression levels in placenta in normotensive, PE and PE/HELLP
expression levels comparingnormotensive (n=59) versus PE (n=28) (A), PE (n=28)versus
n= 87) versus PE/HELLP (n= 17) pregnancies (C). Data are shown as median (thick line) w
Normalized expression levels of ABCG2 in placental samples of different gestational ages (D). O
(n= 28) and closed rounds pregnancies complicated by both PE and HELLP syndrome (n= 1quantitative normalization. In the PE/HELLP group, very little ABCG2
protein is visualized (Fig. 3A). Both ABCG2 mRNA expression and pro-
tein levels are decreased in placenta from PE/HELLP pregnancies
(Fig. 3B).4. Discussion
Based on studies using different techniques to determine speciﬁc
bile acid proﬁles of pregnant women with different pathologies per-
formed between 1977 and 2001, the current view [23] is that during
pregnancy, TBA in the fetal compartment exceed that of the maternal
compartment and that fetal primary bile acids are transferred across
the placenta to the maternal circulation where they are eliminated by
the maternal liver. A recent small sample-sized study (n = 15) con-
ﬁrmed this view [30]. In our cohort of 83 paired maternal/UCB samples
investigated from pregnancies with gestational ages ranging from 26 to
42 weeks of gestation, we observe the opposite. Median TBA levels in
maternal blood are increased compared to UCB, and this increase is
more substantial in case of a preeclamptic pregnancy (Fig. 1A). This dis-
crepancy may be due to the limited sample size of previously reported
series. In contrast to the other studies that report that all acquired sam-
ples were fasting, our samples were not necessarily fasting samples
since they were taken randomly just prior to delivery. A signiﬁcantly
higher proportion of PE/HELLP patients (that have increased TBA levels
compared to normotensive controls and PE patients) were delivered by
primary caesarean section compared to normotensive controls and PE
patients (Supplementary Table 1). Therefore, the number of pre-
operation fasting patients in this group is increased compared to the
more likely non-fasting vaginally delivering patient group. The actual
difference of TBA levels that we have established in the PE/HELLP popu-
lation compared to the normotensive and PE population might even beC
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Fig. 3. Correlation between ABCG2 protein and mRNA levels. The anti-ABCG2 antibody BXP-21 was used for Western blot analysis of ABCG2 on placental samples from 6 normotensive
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TBA [34].
We observe no evidence for net bile acid transport across the placen-
ta, as TBA levels in the umbilical cord arteries (that transport nutrients
and oxygen-rich blood from the placenta to the fetus) and the umbilical
cord vein (carrying waste products and deoxygenated blood from the
fetus to the placenta) are similar (Fig. 1B).
We analyzed the expression level of ABCG2 in placenta as a function
of gestational age, in relation to PE, HELLP syndrome, and with respect
to maternal and UCB TBA levels.
In contrast to previous papers [35–37], we observe a weak positive
correlation of ABCG2 expression with gestational age. Due to the
amount of tissue necessary for this technique, wewere unable to deter-
mine if there is correlation between gestational age and ABCG2 at pro-
tein level for all of our samples. Fig. 2 shows a weak correlation
between gestational age and ABCG2 mRNA in our large cohort of sam-
ples. Since we have groups with similar gestational ages at delivery,
we do not expect a confounding effect of gestational age on ABCG2
levels.
When comparing placentas from pregnancies complicated by HELLP
syndrome to those not afﬂicted by this complication, the expression of
ABCG2 in HELLP placenta is decreased (Fig. 2C) in line with a previous
report on a 1.8-fold down-regulation of ABCG2 in HELLP [38]. It has pre-
viously been shown [39] that ABCG2 expression is lower in placenta
from pregnancies with intrauterine growth restriction not complicated
by PE. Of our 59 normotensive pregnancies, only 3 neonates had a neo-
natal weight below the 10th percentile; thus, no conclusion can be
drawn fromour data regarding this issue. ABCG2 expression is not inﬂu-
enced by mode of delivery [36,40]
In Abcg2−/− mice, TBA levels in both the maternal and the fetal
compartment are increased compared to wild-type mice after gallblad-
der ligation with subsequent obstructive cholestasis 27. It could bespeculated that the lower ABCG2 placental expression in HELLP
syndrome placenta would relate to higher TBA levels in UCB without
affecting levels in the maternal circulation. This shift could not be
demonstrated in the 11 HELLP paired UCB/maternal blood samples
versus the 72 non-HELLP sets.
In conclusion, ABCG2mRNA expression is decreased in the PE/HELLP
but not in the PE placenta. These low levels of mRNA correspond to low
levels of ABCG2 protein in this group. Based on our data, we see no re-
lation between ABCG2 expression in human placenta and TBA levels in
either the maternal or the fetal compartment. As overall TBA levels in
maternal blood are increased compared to umbilical cord blood, we
conclude that the placenta partly protects the fetus from increased ma-
ternal TBA levels. This consistent difference in TBA levels between the
maternal and fetal compartment is unrelated to the placental expres-
sion of ABCG2.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.11.008.
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